Search clinical trials for: Placebo for AG-221

Total 2738 results

Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Celgene

Completed

Radiolabeled Study of AG-221 in Healthy Male Subjects.

Healthy Volunteers
Celgene

Completed

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

Healthy

United States
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Groupe Francophone des Myelodysplasies

Active, not recruiting

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia Acute Myeloid

France
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States
Celgene
Agios Pharmaceuticals, Inc.

Completed

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Hematologic Neoplasms

United States, France
Celgene
Celgene Corporation

Completed

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Glioma | Solid Tumor | Angioimmunoblastic T-cell Lymphoma | Chondrosarcoma | Intrahepatic Cholangiocarcinoma

United States, France
Stanford University
Celgene Corporation

Recruiting

Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation

Leukemia | Leukemia, Myeloid | Monocytic Leukemia

United States
Celgene

No longer available

Expanded Access for AG-221

Acute Myeloid Leukemia

United States
Celgene

Active, not recruiting

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

Leukemia, Myeloid, Acute

United States, France, Italy, Korea, Republic of, Spain, United Kingdom, Australia, Canada, Germany, Netherlands, Portugal, Switzerland, Belgium, Sweden
Agios Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mitapivat (AG-348) in Healthy Adult Participants

Healthy Volunteers

United States
Roswell Park Cancer Institute
Celgene

Withdrawn

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | IDH2 Gene Mutation | Blasts Under 5 Percent of Peripheral Blood White Cells | Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level

United States
Agios Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell Disease

Healthy Volunteers | Anemia, Sickle Cell

United States, Spain, Denmark
University of Liege
Therapiezentrum Burgau

Not yet recruiting

rTMS and EEG in DOC Patients

Disorder of Consciousness

Belgium, Germany
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Myelodysplastic Syndromes

Israel, United States, Korea, Republic of, Australia, France, Germany, Spain, United Kingdom, Czechia, Austria, Italy, Greece, Poland
MediciNova

Completed

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

Asthma

United States
Agios Pharmaceuticals, Inc.

Completed

A Phase I Study of AG-348 in Healthy Volunteers (AG-348MAD)

Healthy Volunteer

United States
MediciNova

Completed

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

Asthma

United States
Icosavax, Inc.

Completed

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

Healthy

United States
MediciNova

Completed

Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Chronic Obstructive Pulmonary Disease

United States
Vascular Biogenics Ltd. operating as VBL Therapeutics

Completed

Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers

Biomarker

United Kingdom
Institut de Recherches Internationales Servier

Active, not recruiting

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Recurrent Glioma | Grade 2 Glioma | Residual Glioma

United States, Canada, Spain, Italy, United Kingdom, Switzerland, Israel, Japan, Netherlands, Germany, France
Columbia University
National Institute of Mental Health (NIMH)

Enrolling by invitation

Adolescent Depression Screening and Treatment in Mozambican Primary Care

Depression | Adolescent Behavior

Mozambique
Kezar Life Sciences, Inc.

Recruiting

KZR-261 in Subjects With Advanced Solid Malignancies

Advanced/Metastatic Solid Tumor

United States
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)

Completed

Group Interpersonal Psychotherapy for Depressed Adolescents in School-based Clinics

Depression
Akros Pharma Inc.

Completed

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

Diabetes Mellitus

United States
Ferozsons Laboratories Ltd.

Unknown

Role of ProTectis on Infant Colic and Its Effect on Infant Crying Time and Maternal Mental Health (PRIC-SMM)

Infantile Colic | Infant Sleeping Habits | Maternal Mental Health.

Pakistan
Immorna Biotherapeutics, Inc.
ICON plc

Recruiting

A Phase 1/2 Study to Assess the Safety and Immunogenicity of JCXH-221, an mRNA-based Broadly Protective COVID-19 Vaccine

COVID-19 | Infectious Disease

United States
West German Center of Diabetes and Health
gbo Medizintechnik AG

Completed

HTEMS Treatment of Diabetic Polyneuropathy (HTEMS-RCT)

Diabetic Polyneuropathy

Germany
Tactile Systems Technology, Inc.

Terminated

Flexitouch Treatment for Venous Ulcers

Venous Ulcer

United States
QLT Inc.

Terminated

A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

End Stage Renal Disease

United States
Agios Pharmaceuticals, Inc.

Recruiting

A Safety Study of Single and Multiple Doses of AG-181 in Healthy Participants

Healthy Volunteers

United States
NYU Langone Health

Recruiting

Modulating Movement Intention Via Cortical Stimulation

Seizures | Seizure Disorder | Psychogenic Movement Disorder

United States
PegBio Co., Ltd.

Completed

Clinical Trial for the Investigational Drug (PB-201) in Subjects With Type 2 Diabetes Mellitus

Type2 Diabetes Mellitus

China
Beersheva Mental Health Center

Unknown

Neurofeedback Using TMS as an Assessment Tool

Brain Diseases

Israel
Agios Pharmaceuticals, Inc.

Terminated

A Safety and Tolerability Study of AG-519 in Healthy Subjects

Anemia

United Kingdom
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections

Acute Upper Respiratory Infections

Russian Federation
SK Chemicals Co., Ltd.

Completed

Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB

Overactive Bladder

Korea, Republic of
Lund University
Skane University Hospital; Vinnova; Carbiotix AB

Active, not recruiting

Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes

Diabetes Type 2

Sweden
Agios Pharmaceuticals, Inc.

Completed

A Phase I Study of AG-348 in Healthy Volunteers (AG-348 SAD)

Healthy Volunteer

United States
Global Alliance for TB Drug Development

Completed

Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects

Tuberculosis | Tuberculosis, Pulmonary

United States
TWi Biotechnology, Inc.

Completed

Study of AC-201 in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Taiwan
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) (ENERGIZE)

Non-Transfusion-dependent Alpha-Thalassemia | Non-Transfusion-dependent Beta-Thalassemia

Spain, Taiwan, Thailand, United Kingdom, Malaysia, United States, Netherlands, Bulgaria, Turkey, Italy, Canada, Brazil, France, United Arab Emirates, Denmark, Greece, Lebanon, Saudi Arabia
Agenus Inc.

Completed

Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes

Herpes Simplex Type 2

United States
Helsinki University Central Hospital

Completed

Target-controlled Infusion Versus Patient-controlled Sedation With Propofol in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Sedation

Finland
Agios Pharmaceuticals, Inc.

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) (ENERGIZE-T)

Transfusion-dependent Alpha-Thalassemia | Transfusion-dependent Beta-Thalassemia

Spain, Taiwan, Thailand, United States, France, Canada, Malaysia, Germany, Netherlands, Bulgaria, United Kingdom, Turkey, Italy, Greece, United Arab Emirates, Brazil, Denmark, Lebanon, Saudi Arabia
MediciNova

Terminated

Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma

Asthma | Status Asthmaticus

United States
Institut für Diabetes-Technologie Forschungs- und...

Completed

System Accuracy Evaluation of 2 CE-marked Blood Glucose Monitoring System

Diabetes

Germany

Search clinical trials for: Placebo for AG-221

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations